Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, multinational randomised DBPC clinical trial for evaluation of safety and efficacy of specific immunotherapy with recombinant major allergens of Timothy grass pollen adsorbed onto aluminium-hydroxide in patients with IgE-mediated allergic rhinoconjunctivitis +/- controlled asthma.

Trial Profile

Multicentre, multinational randomised DBPC clinical trial for evaluation of safety and efficacy of specific immunotherapy with recombinant major allergens of Timothy grass pollen adsorbed onto aluminium-hydroxide in patients with IgE-mediated allergic rhinoconjunctivitis +/- controlled asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2013

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Asthma; Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMETHYST
  • Most Recent Events

    • 08 Mar 2013 Planned end date changed from 1 Oct 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Actual initiation date changed from Mar 2008 to Jan 2008 as reported by European Clinical Trials Database.
    • 15 Mar 2012 Planned number of patients changed from 498 to 750 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top